Alexion Pharmaceuticals Inc.'s acquisition of Achillion Pharmaceuticals Inc. will add two clinical-stage drugs that will build on Alexion's own expertise in complement alternative pathway-mediated rare diseases. Achillion is developing oral small molecule Factor D inhibitors for diseases like paroxysmal nocturnal hemoglobinuria (PNH), where Alexion is the current market leader with its C5 inhibitor Soliris (eculizumab) and second-generation drug Ultomiris (ravulizumab).
"The addition of clinical-stage oral Factor D inhibitors that have potential to advance the standard of care for multiple rare,...
